COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO
NCT ID: NCT06880042
Last Updated: 2025-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
EARLY_PHASE1
60 participants
INTERVENTIONAL
2025-05-01
2025-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparitive Study Between Uvb Alone and Uvb With Topical Tacrolimus 0.03% for the Treatment of Vitiligo
NCT05577637
Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo
NCT03199664
Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo
NCT07044141
Comparison of Needling and Microneedling Plus Phototherapy in Localized Vitiligo Patients
NCT06991972
Combined Effect of Acitretin and Narrow Band Ultraviolet B on Vitiligo Repigmentation
NCT04245319
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tacrolimus
Patient of Limited vitiligo less than 20% BSA will be treated with topical tacrolimus and narrowband UVB
Tacrolimus
Tacrolimus is calcineurin inhibitor that will act as immunomodulator
Calcipotriol
Calcipotriol is a vitamin D analogue that will act as immunomodulator
Calcipotriol
Calcipotriol is a vitamin D analogue that will act as immunomodulator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tacrolimus
Tacrolimus is calcineurin inhibitor that will act as immunomodulator
Calcipotriol
Calcipotriol is a vitamin D analogue that will act as immunomodulator
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Skin malignancy or any other malignant skin condition.
* Photo induced or photo aggravated dermatosis like (SLE, photodermatitis, rosacea, psoriasis, pemphigus vulgaris) along with vitiligo.
* Prior history of allergy to tacrolimus or calcipotriol.
* Other form of treatment for vitiligo within at least 1 month.
15 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr ayesha wahid
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr ayesha wahid
Awahid
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lahore general.hospital
Lahore, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LGH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.